OverviewSuggest Edit

Fluidigm creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents.

TypePublic
Founded1999
HQSouth San Francisco, CA, US
Websitefluidigm.com
Employee Ratings3.9
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2019)566(+6%)
Job Openings31
Revenue (FY, 2020)$138.1 M(+18%)
Share Price (Sept 2021)$6.6(-3%)
Cybersecurity ratingBMore

Key People/Management at Fluidigm

Chris Linthwaite

Chris Linthwaite

President and CEO
Vikram Jog

Vikram Jog

Chief Financial Officer
Nick Khadder

Nick Khadder

Senior Vice President, General Counsel and Corporate Secretary
Colin McCracken

Colin McCracken

Chief Commercial Officer
Show more

Fluidigm Office Locations

Fluidigm has offices in South San Francisco, Sydney, Markham, Les Ulis and in 5 other locations
South San Francisco, CA, US (HQ)
7000 Shoreline Ct #100
South San Francisco, CA, US
2 Tower Pl Suite 2000
Sydney, AU
50 Bridge St
Markham, CA
1380 Rodick Rd #400
Les Ulis, FR
1 Avenue de l'Atlantique
München, DE
Landaubogen 10
Show all (12)

Fluidigm Financials and Metrics

Fluidigm Revenue

Fluidigm's revenue was reported to be $138.14 m in FY, 2020
USD

Revenue (Q1, 2021)

32.8m

Net income (Q1, 2021)

(18.8m)

EBIT (Q1, 2021)

(19.3m)

Market capitalization (15-Sept-2021)

497.0m

Closing stock price (15-Sept-2021)

6.6

Cash (31-Mar-2021)

49.7m

EV

541.5m
Fluidigm's current market capitalization is $497 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

42.9m52.3m71.2m116.5m114.7m104.4m101.9m113.0m117.2m138.1m

Revenue growth, %

64%(1%)(9%)

Cost of goods sold

13.2m300.0k300.0k300.0k300.0k300.0k45.0m51.3m53.0m

Gross profit

29.7m52.0m70.9m116.2m114.4m104.1m56.9m61.6m64.3m
Quarterly
USDQ2, 2011

Financial Leverage

1.4 x
Show all financial metrics

Fluidigm Operating Metrics

FY, 2016

Patents Issued

600
Show all operating metrics

Fluidigm Revenue Breakdown

Embed Graph

Fluidigm revenue breakdown by geographic segment: 50.4% from United States, 28.5% from Europe, 17.7% from Asia-Pacific and 3.4% from Other

Fluidigm Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Fluidigm Online and Social Media Presence

Embed Graph

Fluidigm Company Culture

  • Overall Culture

    B+

    74/100

  • CEO Rating

    B+

    73/100

  • Compensation

    A+

    85/100

Learn more on Comparably

Fluidigm News and Updates

Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financi…

Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry

Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System

Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine

Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development

Medical Technology Firm Fluidigm Is Said to Explore Sale

Medical Technology Firm Fluidigm Is Said to Explore Sale

Fluidigm to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in several upcoming invest…

Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report first quarter 2021 financial results on Thursday, M…
Show more

Fluidigm Blogs

Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit

Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit Content Import Mon, 08/09/2021 - 11:15 Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit Aug 9, 2021 This release is a backfill from a News Wire …

Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million . SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools

Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif. , July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2021 financial results on Thursday,

Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time

SOUTH SAN FRANCISCO, Calif. , May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will host a virtual investor event that will showcase competitive

Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period

Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,

Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to $138.1 million Collaboration with PLT Tech to Market CyTOF Technology to Clinical Labs in China SOUTH
Show more

Fluidigm Frequently Asked Questions

  • When was Fluidigm founded?

    Fluidigm was founded in 1999.

  • Who are Fluidigm key executives?

    Fluidigm's key executives are Chris Linthwaite, Vikram Jog and Nick Khadder.

  • How many employees does Fluidigm have?

    Fluidigm has 566 employees.

  • What is Fluidigm revenue?

    Latest Fluidigm annual revenue is $138.1 m.

  • What is Fluidigm revenue per employee?

    Latest Fluidigm revenue per employee is $244.1 k.

  • Who are Fluidigm competitors?

    Competitors of Fluidigm include Cytek Biosciences, Aclara and Dren Bio.

  • Where is Fluidigm headquarters?

    Fluidigm headquarters is located at 7000 Shoreline Ct #100, South San Francisco.

  • Where are Fluidigm offices?

    Fluidigm has offices in South San Francisco, Sydney, Markham, Les Ulis and in 5 other locations.

  • How many offices does Fluidigm have?

    Fluidigm has 12 offices.